Global Amniotic Membrane Market Report by Application (Ophthalmology, Surgical Wounds, Others) Product (Lyophilization Amniotic Membrane, Cryopreserved Amniotic Membrane) End User (Speciality Clinics, Hospital, Ambulatory Surgical Centers, Research & Acad

Global Amniotic Membrane Market Report by Application (Ophthalmology, Surgical Wounds, Others) Product (Lyophilization Amniotic Membrane, Cryopreserved Amniotic Membrane) End User (Speciality Clinics, Hospital, Ambulatory Surgical Centers, Research & Academic Institutes) Countries and Company Analysis, 2024-2032

Amniotic Membrane Market Analysis

The Global Amniotic Membrane Market size will surpass US$ 6,588.2 Million by 2032 from US$ 2,437.7 Million in 2023, with a CAGR of 11.68% from 2024 to 2032. Some of the main reasons driving the market include the growing demand for minimally invasive (MI) treatments, the rise in the prevalence of various chronic illnesses like rheumatoid arthritis and diabetes, and the growth of specialist clinics and hospitals.

Amniotic Membrane Market Outlook

The placenta's interior most layer, the amniotic membrane, is made up of an avascular stromal matrix and a thick foundation membrane. Because of its special qualities, this biological tissue—which comes from the placenta—is used in medical applications. By controlling inflammatory reactions, it lessens tissue fibrosis and scarring while also reducing inflammation. It shortens the healing times of burns and severe wounds by relaxing them. It is frequently utilized in procedures for conditions affecting the ocular surface, like corneal ulcers, it is safe, well-tolerated, and has a low rejection rate. It is also used as a biological dressing to improve healing and lessen adhesions.

The amniotic membrane is being used in more surgical operations as a result of patients' growing demand for minimally invasive (MI) therapies. Amniotic membrane therapy implementation is also becoming increasingly feasible due to the development of specialized clinics and hospitals, as well as the expansion of the healthcare infrastructure. In addition, in order to broaden their reach, exchange knowledge, and penetrate new markets, a number of prominent industry participants are concentrating on mergers and acquisitions (M&A). Additionally, businesses are continuously expanding the range of products they offer, including amniotic membranes customized for different surgical and medicinal applications. Additionally, a number of nations' governments are stepping up their campaigns to inform medical professionals and people about the uses and advantages of amniotic membranes, which is promising for the industry.

Driving Forces of Global Amniotic Membrane Market-

The market is expanding because to the increased prevalence of burn injuries:

The rising demand for biologics used in wound treatment, such as amniotic membranes, is propelling the growth of the amniotic membrane market. Nearly two-thirds of burn cases occur in the WHO's African and Southeast Asian regions, and the majority happen in low- and middle-income economies. For example, every year in India, one million people suffer from mild to severe burns. Bangladesh and Nepal are two more Southeast Asian countries with significant burn incidence rates. Every year, 173,000 children in Bangladesh are thought to have moderate to severe burns. Burns rank second most common type of wound in Nepal, making up 5% of all impairments.

Furthermore, the frequency of transplants has increased in recent years due to increased awareness, which has raised demand for these tissue-based therapies. Additionally, as more people become aware of the need for donations, market revenue has grown. As an illustration, Amniox Medical, Inc., a Tissue Tech, Inc. company that pioneered the clinical use of human birth tissue products, debuted a new awareness campaign in June 2021 that highlighted the company's extensive line of human birth tissue-based products designed to speed up wound healing and reduce associated medical costs. The campaign examines the financial burden that treating complicated wounds places on healthcare systems and emphasizes evidence-based quality management.

It is anticipated that an increase in R&D efforts to create new products and boost amniotic membrane efficacy would contribute to the market's expansion. For example, American regenerative medicine company Amnio Technologies began Phase II clinical trials in November 2020 to investigate the effectiveness of their product, PalinGen, an amniotic membrane allograft used to treat diabetic ulcers.

An increase in the population that is older:

The treatment of numerous eye surface infections, such as ocular dystrophy, cataracts, corneal ulcers, bacterial keratitis, glaucoma, bullous keratopathy, corneal degeneration, eyelid reconstruction, and more, is greatly aided by these tissue-based therapies. There is a considerable demand for these items as a result of the enormous increase in ophthalmology surgery caused by the global aging population. According to data released by the Centers for Disease Control and Prevention (CDC), about one million people suffer from eye infections each year.

It is primarily used as a biological bandage for wound care and treatment, as well as a surgical transplant. These membranes function as a supporting scaffold to aid in the process of re-epithelization when employed as a graft. Accordingly, Amniox Medical launched an awareness campaign in June 2021 to highlight the usefulness of its tissue-based solutions in lowering the expenses related to wound healing. These drugs, with their anti-inflammatory and anti-scarring qualities, are very helpful in reducing patients' increased discomfort and inflammation, especially in situations of burn injuries.

North America Amniotic Membrane Market

Because of its highly established healthcare infrastructure, significant healthcare expenditures, and recent developments by market competitors, North America is the largest regional market in terms of revenue. For example, the United States Centers for Medicare & Medicaid Services released statistics in February 2023 that shows that, in comparison to 2020, national healthcare spending climbed by 2.7% to USD 4.3 trillion in 2021.

Furthermore, it is projected that the major innovations made by industry participants will accelerate market expansion in North America. For example, TissueTech was granted approval by the Food and Drug Administration (FDA) in March 2021 to carry out a Phase 2 trial employing cryopreserved umbilical cord (CUC) and cryopreserved amniotic membrane (CAM) that has been morselized (IND# TTBT01).

Once more, in May 2021, Vivex Biologics, Inc.—a premier provider of naturally sourced therapies in the field of regenerative medicine—introduced Viagenex, a line of amniotic allografts that are processed to preserve the rich supply of extracellular matrix, growth factors, and cytokines as well as the intrinsic mechanical properties of amniotic tissue. As a result, the region's amniotic membrane market is anticipated to rise as a result of the intense product development taking place in several North American nations.

Global Amniotic Membrane Company Analysis:

Some leading Amniotic Membrane companies are Stryker Corporation, Smith & Nephew plc, Integra LifeSciences Holdings, MiMedx, Organogenesis Net, Wright Medical Group Inc, Applied Biologics LLC, FzioMed Inc, Katena, Inc., Tissue-Tech Inc.

Global Amniotic Membrane Company News:

March 2023: NuVision, a Nottingham-based health technology business, has secured £1.1 million in funding for its inner layer of the placenta-based contact lenses and wound dressing.
November 2022: Verséa Ophthalmics introduced a number of products, one of which is the Biovance, a hybrid next-generation amniotic membrane made up of three layers of amnion.
February 2022: Amnio Technology, a pioneer in the creation and marketing of amniotic tissue allografts worldwide, has introduced two new palingen membrane products: dual-layer palingen x-membrane and palingen dual-layer membrane. The novel allografts are homologous usage, chorion-free, and require little modification, just like the rest of the PalinGen membrane product line. Patients with complex and/or open surgical wounds, burns, and non-healing acute and chronic wounds might consider the use of the Palingen dual-layer membrane and the PalinGen X-membrane.
January 2022: Akorn Operating Company LLC and Laboratoires Thea SAS, one of the top independent pharmaceutical companies in Europe, have entered into a purchase agreement for seven branded ophthalmic products, including AcellFX (acellular amniotic membrane), which offers an environment or covering that protects the ocular surface while it is being repaired.

Product –Market Breakup in 2 Viewpoints –

1. Cryopreserved Amniotic Membrane
2. Lyophilization Amniotic Membrane

Application – Market Breakup in 3 Viewpoints –

1. Surgical Wounds
2. Ophthalmology
3. Others

End Users – Market Breakup in 4 Viewpoints –

1. Hospital
2. Ambulatory Surgical Centers
3. Speciality Clinics
4. Research & Academic Institutes

Geography – Market Breakup of 23 countries -

• North America

o United States
o Canada
o Colombia

• Europe

o France
o Germany
o Italy
o Spain
o United Kingdom
o Netherlands

• Asia Pacific

o China
o Japan
o India
o Australia
o South Korea
o Malaysia
o Indonesia
o Israel

• Latin America

o Brazil
o Mexico
o Argentina

• Middle East & Africa

o South Africa
o Saudi Arabia
o UAE

• ROW

Company Insights:

• Overview
• Recent Development
• Product Portfolio
• Revenue

Key Players Analysis:

1. Stryker Corporation
2. Smith & Nephew plc
3. Integra LifeSciences Holdings
4. MiMedx
5. Organogenesis Net
6. Wright Medical Group Inc
7. Applied Biologics LLC
8. FzioMed Inc
9. Katena, Inc.
10. Tissue-Tech Inc